These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25252953)

  • 21. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
    Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
    J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total steroidal alkaloids from Veratrum patulum L. Inhibit platelet aggregation, thrombi formation and decrease bleeding time in rats.
    Song Q; Wang S; Zhao W
    J Ethnopharmacol; 2012 May; 141(1):183-6. PubMed ID: 22366682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quick reference guide to the new oral anticoagulants.
    Hurst K; Lee R; Handa A
    J Vasc Surg; 2016 Jun; 63(6):1653-7. PubMed ID: 27113315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invited commentary.
    Henke PK
    J Vasc Surg; 2010 Nov; 52(5):1270-1. PubMed ID: 21050988
    [No Abstract]   [Full Text] [Related]  

  • 27. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
    Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
    J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
    Klamroth R; Gottstein S; Essers E; Landgraf H
    Vasa; 2010 Aug; 39(3):243-8. PubMed ID: 20737383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs.
    Lunsford KV; Mackin AJ; Langston VC; Brooks M
    J Am Anim Hosp Assoc; 2009; 45(6):261-7. PubMed ID: 19887383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version.
    Qneibi D; Ramacciotti E; Macedo AS; Caffaro RA; Agati LB; Siddiqui F; Kouta A; Hoppensteadt D; Fareed J; Carter CA
    Clin Appl Thromb Hemost; 2020; 26():1076029620960820. PubMed ID: 32996340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers.
    Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
    Harenberg J; Kalodiki E; Walenga JM;
    Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.
    Luna E; Agrawal P; Mehta R; Vernhes C; Viskov C; Amiral J; Warren WL; Drake DR
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):211-22. PubMed ID: 25525049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical and statistical comparability of generic enoxaparins from the US market with the originator product.
    Mourier PA; Agut C; Souaifi-Amara H; Herman F; Viskov C
    J Pharm Biomed Anal; 2015 Nov; 115():431-42. PubMed ID: 26280926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
    Turpie AG; Gallus AS; Hoek JA;
    N Engl J Med; 2001 Mar; 344(9):619-25. PubMed ID: 11228275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombotic potential of esculin 7, 3', 4', 5', 6'-O-pentasulfate (EPS) for its role in thrombus reduction using rat thrombosis model.
    Ahmad I; Sharma S; Gupta N; Rashid Q; Abid M; Ashraf MZ; Jairajpuri MA
    Int J Biol Macromol; 2018 Nov; 119():360-368. PubMed ID: 30009901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.